GAITHERSBURG, Md., Sept. 5, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will participate in in Citi's 18th Annual Biopharma Conference from Tuesday, September 5 to Thursday, September 7, 2023.

Dr. David Shao, YS Biopharma Chief Executive Officer, and other members of the Company's management team will attend and will be available for one-on-one and small group meetings.

For more information on the conference, please contact your conference representative. Meeting requests may also be emailed to This email address is being protected from spambots. You need JavaScript enabled to view it..

About YS Biopharma

YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA^® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharm.com.

Investor Relations Contacts
Alyssa Li
Director of Investor Relations
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.